Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Azenta's average EBITDA Per Share Growth Rate was -23.60% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 28.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 26.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Azenta was 87.70% per year. The lowest was -52.90% per year. And the median was 2.30% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
Azenta 5-Year EBITDA Growth Rate Related Terms
FRA:BA3 vs KMTS, STAA, BLFS: 5-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Azenta's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Azenta 5-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Azenta's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Azenta's 5-Year EBITDA Growth Rate falls into.
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 5-Year EBITDA Growth Rate of 26.50% mean?
Azenta (FRA:BA3) has a 5-Year EBITDA Growth Rate of 26.50% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Azenta and its competitors.
Is Azenta's 5-Year EBITDA Growth Rate too high?
Azenta's current 5-Year EBITDA Growth Rate is 26.50%. Overall, Azenta has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Azenta's 5-Year EBITDA Growth Rate compare to KMTS and STAA?
Azenta's 5-Year EBITDA Growth Rate of 26.50% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
A good 5-Year EBITDA Growth Rate depends on the Medical Devices & Instruments industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Azenta and its competitors. Azenta's current 5-Year EBITDA Growth Rate is 26.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Azenta stock overvalued right now?
Based on GuruFocus' analysis, Azenta (FRA:BA3) is currently considered Significantly Undervalued. The stock's GF Value™ is €45.14, compared to a current price of €28.40 — trading 37.1% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 26.50%. Azenta's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Azenta (FRA:BA3), the current 5-Year EBITDA Growth Rate is 26.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Azenta (FRA:BA3) Overvalued in 2026?
Based on GuruFocus' analysis, Azenta stock appears to be undervalued.
The current stock price of €28.40 is trading 37.1% below its estimated GF Value™ of €45.14.
GuruFocus considers Azenta to be Significantly Undervalued.
Key valuation signals for FRA:BA3:
5-Year EBITDA Growth Rate: 26.50%
GF Value™: €45.14 vs. price of €28.40 (37.1% below fair value)
No single metric tells the full story. See the FRA:BA3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.
78GF Score
Get the complete analysis for FRA:BA3
5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BA3 has been successfully added to your 
